Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danilo Perrotti

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Oncogene|December 12, 2002
Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteinsDanilo Perrotti, Bruno Calabretta
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the wayDanilo Perrotti, Paolo Neviani
Oncogene|April 20, 2004
Translational regulation by the p210 BCR/ABL oncoproteinDanilo Perrotti, Bruno Calabretta
The Lancet. Oncology|May 4, 2013
Protein phosphatase 2A: a target for anticancer therapyDanilo Perrotti, Paolo Neviani
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
SETting OP449 into the PP2A-activating drug familyPaolo Neviani, Danilo Perrotti
Cancer Metastasis Reviews|January 24, 2008
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemiasDanilo Perrotti, Paolo Neviani
Blood|February 26, 2004
The biology of CML blast crisisBruno Calabretta, Danilo Perrotti
Leukemia & Lymphoma|February 9, 2011
BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic interventionDanilo Perrotti, Jason G Harb
Frontiers in Oncology|March 13, 2015
From the Biology of PP2A to the PADs for Therapy of Hematologic MalignanciesMaria Ciccone, George A Calin, Danilo Perrotti
The Journal of Clinical Investigation|July 2, 2010
Chronic myeloid leukemia: mechanisms of blastic transformationDanilo Perrotti, Catriona Jamieson, John Goldman, et al.
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Oncogene|December 12, 2002
Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteinsDanilo Perrotti, Bruno Calabretta
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the wayDanilo Perrotti, Paolo Neviani
Oncogene|April 20, 2004
Translational regulation by the p210 BCR/ABL oncoproteinDanilo Perrotti, Bruno Calabretta
The Lancet. Oncology|May 4, 2013
Protein phosphatase 2A: a target for anticancer therapyDanilo Perrotti, Paolo Neviani
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
SETting OP449 into the PP2A-activating drug familyPaolo Neviani, Danilo Perrotti
Cancer Metastasis Reviews|January 24, 2008
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemiasDanilo Perrotti, Paolo Neviani
Blood|February 26, 2004
The biology of CML blast crisisBruno Calabretta, Danilo Perrotti
Leukemia & Lymphoma|February 9, 2011
BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic interventionDanilo Perrotti, Jason G Harb
Frontiers in Oncology|March 13, 2015
From the Biology of PP2A to the PADs for Therapy of Hematologic MalignanciesMaria Ciccone, George A Calin, Danilo Perrotti
The Journal of Clinical Investigation|July 2, 2010
Chronic myeloid leukemia: mechanisms of blastic transformationDanilo Perrotti, Catriona Jamieson, John Goldman, et al.
Pageof 9